LARVOL, a providesr of SaaS solutions to support the data and intelligence needs of the pharmaceutical and biotech industry, announced on Tuesday that it has appointed Mark Lagunowich as vice president, Global Sales.
With more that 30 years of experience in the life science industry, Lagunowich most recently led the Americas Life Science Sales Team for Clarivate Analytics.
Previously, Lagunowich worked as Global VP of Sales at Sparta Systems for eight years, selling a wide variety of business solutions to pharmaceutical, medical device, and clinical research (CRO) companies.
Lagunowich's appointment adds to several important new hires for LARVOL, including HR and Marketing leadership roles, as the company prepares to launch additional oncology-focused solutions in 2021. These include VIEW, a social listening platform aimed at capturing the conversations of oncology opinion leaders on Twitter, which will launch at ScaleUp 360 in April, along with CLIN, a complete database of immuno-oncology clinical trial data that will also launch in spring this year.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA